Subscribe to Rupya
|
Biocon net profit declines 33.10% to Rs 30.01 crore in the first Qtr for june ending 2008-2009 compared to Rs 44.86 crore in same QOQ Previous year 2007. Sales declined 2.74% to Rs 221.18 crore in the first Qtr for june ending 2008-2009 compared to Rs 227.40 crore in same QOQ Previous year 2007.
Jubilant Organosys announces its first QTR Results for 2008-2009.Net profit was at Rs 12.76 crore versus Rs 142.9 crore when compared to the same QTR for previous year , ok i understand is the figure wrong or something no it is right they had a huge forex loss of 107.6 crore this qtr but the same was like 82 crore gain previous year same qtr. Q1 net sales is at Rs 826.6 crore versus Rs 540 crore on YoY basis.
So on thursday ranbaxy was down like to 216 rs because ranbaxy told the market that they are not interested in hostile takeover , may be thats the strategy they say it and get orchid chemical price down and had Solrex acquire 3.32% stake in Orchid Chemicals on Friday, reports CNBC-TV18. The company shareholding in the Indian Pharmaceuticals major has reached 14.72%, which is close to 15% open offer trigger. Sources said other Ranbaxy promoter group companies might have also garnered shares in Orchid.
Orchid Chemicals & Pharmaceuticals Ltd has informed the market that the Company is announcing, on April 10, 2008 the formation of its wholly owned subsidiary in Japan called Orchid Pharma Japan K K (Orchid Japan). Orchid Japan, is headquartered in Tokyo, will drive Orchid’s foray into the high potential and growing Japanese generics market.
Ranbaxy commented that they don’t believe in hostile takeover , this statement was enough to sell orchid chemicals which rose from prev week of 140 rs or so to this weeks 240 rs .There was speculation that Solrex Pharmaceuticals, which recently increased its holding in Orchid to 11.4% is controlled by Ranbaxy. Orchid stock had spurted in the last two days on such buzz.The acquisition of Orchid shares by Solrex Pharmaceuticals through open market purchases raised expectations that Ranbaxy plans a hostile takeover of Orchid Chemicals
Orchid Chemicals was hammered today by 40 percent or so and its trading at 128 and it closed the market on friday at 208.60 , infact hindu has reconmmended a Buy on this stock on saturday .The traded quantity in the stock is unusally high.
Hindu Recommends a Buy for Orchid Chemicals on saturday
Update: Reason for the sell off
The Orchid management told CNBC-TV18 that they have sold 7% of their stake due to margin calls.After Bear Stearns transferred over 10 lakh Orchid shares, the stock price was under considerable pressure. As the margin calls positions are being cleared, they have no further plans to sell more shares, the management said.
Nicholos piramal which changed its name to Piramal Healthcare like previous week or so now has a new identity or logo , They call the identity as a Gyan Mudra .The stock price of Nicholos piramal went up by 16.50 rs or 6 percent in BSE today.You can see the new Gyan Mudra identity of Piramal Healthcare in the picture below.
About Aurobindo Pharma
| One of the largest API manufacturers in Asia, Aurobindo Pharma has commercialised over hundred APIs. Aurobindo’s products are spread over six major areas encompassing Antibiotics, Anti-Retro Virals, CVS, CNS, Gastroenterologicals, and Anti-Allergics. |  |
Aurobindo’s R & D strengths lie in developing intellectual property in non-infringing processes and resolving complex chemistry challenges. In the process, Aurobindo develops new drug delivery systems, dosage formulations and applies new technology for better processes.
Sector :Pharmaceuticals - Bulk Drugs
Stock Price
Aurobindo Pharma is trading at 304 rs or so which was on march 7th 2008 and its just 7 times the EPs of 43 or so , while considering other phrama company at this price its considered a good buy.
Track Aurobindo Stock Price here.
Budget Benefits
•Reduction of excise duty from 16% to 8% is a positive for all pharma companies .
•Emphasis on allocating funds for the eradication of HIV/AIDS and polio .
Read the rest of this entry »
Nicholas Piramal India Ltd informed the market that at its meeting held on March 03, 2008, has approved the proposal for change of name of the Company from “Nicholas Piramal India Ltd” to “Piramal Healthcare Ltd”.The Health Sector dint see much red sides today and this scrip also dint go much down today.
Shasun Chemicals & Drugs Ltd saw some movement in the price today after it informed the market that they have entered into a non-exclusive licensing agreement with Merck & Co., Inc.This will bring more business from Merck.
Jubilant Organosys Ltd informed the market that it has bagegd new contracts worth US $ 92 million for its Proprietary Products and Exclusive Synthesis segment under CRAMS business for the present calendar year (CY 2008).
Bliss GVS Pharma rose 5433.33% to Rs 8.30 crore in Qtr Dec 2007 compared to Rs 0.15 crore QOQ in Dec 2006. Sales rose 2084.31% to Rs 22.28 crore in Qtr Dec 2007 compared to Rs 1.02 crore QOQ in Dec 2006.
Orchid Chemicals & Pharmaceuticals rose 91.07% to Rs 54.11 crore in qtr Dec 2007 as against Rs 28.32 crore in qtr Dec 2006. Sales rose 39.36% to Rs 332.69 crore in qtr Dec 2007 as against Rs 238.73 crore in qtr Dec 2006.
Sanjivani Paranteral Ltd has announced the market that it has entered into supply contract for a period of two years with Government of Maharashtra by DMER for the supply of its 9 products to more than 100 Civil Hospitals & Medical Collages in entire Maharashtra State Government’s .
Bliss GVS Pharma Ltd has informed BSE that the Company has received an order of Rs 25.00 crores for supply of Anti malarial Drugs for African Countries.